Invivo Therapeutics Holdings (NVIV) 16.69 $NVIV
Orphan Drug Product Candidate Development Provides Revolutionary Solutions for Treatment of Severe Injuries and Innovative Therapies for Rare Diseases & Conditions
PR Newswire - Wed Jul 15, 7:15AM CDT
As modern biotechnology continues to provide breakthrough products and technologies to combat debilitating rare diseases, treat severe injuries and offer therapeutic treatments for many areas of various medical conditions, today's leading biotech & biopharmaceutical companies such as Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Receptos, Inc. (NASDAQ: RCPT) race to introduce the newest technologies and products that help improve the lives and overall health of patients worldwide.
NVIV: 16.69 (+0.13), CLDX: 25.56 (-0.83), RCPT: 228.98 (+0.26), EPRS: 6.99 (-0.66), ARIA: 8.24 (-0.17), CELG: 136.24 (+1.01)
Third patient receiving InVivo's Neuro-Spinal Scaffold shows encouraging progress, shares up 10% premarket
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 8:26AM CDT
NVIV: 16.69 (+0.13)
InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold
Business Wire - Mon Jul 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury.
NVIV: 16.69 (+0.13)
InVivo Therapeutics to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
Business Wire - Wed Jul 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at Cantor Fitzgerald's Inaugural Healthcare Conference to be held Wednesday, July 8, 2015 at Le Parker Meridien Hotel in New York City, NY. The company's presentation will be at 10:45 A.M. (EDT).
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Rutgers New Jersey Medical School as New Clinical Site for Neuro-Spinal Scaffold
Business Wire - Tue Jun 30, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Rutgers New Jersey Medical School in Newark, NJ has been added as a clinical site in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Robert Heary, M.D., Professor of Neurological Surgery and Director of the Spine Center, has been named Principal Investigator at this site. The Spine Center is part of the Northern New Jersey Spinal Cord Injury System, one of 14 federally designated Spinal Cord Injury Model Systems in the United States and the only one in the state of New Jersey.
NVIV: 16.69 (+0.13)
InVivo Therapeutics is Added to Russell Global, Russell 3000(R), Russell 2000(R), and Russell Microcap(R) Indexes
Business Wire - Mon Jun 29, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company has been added to the Russell Global, Russell 3000(R), Russell 2000(R), and Russell Microcap (R) Indexes on June 26, 2015.
NVIV: 16.69 (+0.13)
InVivo Therapeutics up 5% premarket on patent award covering Neuro-Spinal Scaffold
Seeking Alpha - at Seeking Alpha - Mon Jun 22, 8:16AM CDT
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders Meeting
Business Wire - Fri Jun 19, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the posting of the management presentation recording from the 2015 Annual Shareholders Meeting held on June 16th, 2015. The recording is available on the investor relations page of InVivo's website - http://www.invivotherapeutics.com/investor-re...l-meeting/.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Co-Founder Dr. Robert Langer to Highlight InVivo Scientific Progress in Closing Keynote Address at the International Society for Stem Cell Research 2015 Annual Meeting
Business Wire - Thu Jun 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Co-Founder Robert Langer, Sc.D., will be making the Closing Keynote Address at the Annual Meeting of the International Society for Stem Cell Research (ISSCR), to be held June 24-27, 2015 in Stockholm, Sweden. His keynote address will be held during the last plenary session titled Making Tissues and Organs.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Appointment of Ann Merrifield as Lead Director
Business Wire - Tue Jun 16, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the Company's Board of Directors has appointed independent director Ann Merrifield to the newly created position of Lead Director. The Lead Director will serve as a liaison between the Chairman and non-management directors, chair all executive sessions, and work with the Chairman on meeting agendas and time schedules for the Board of Directors.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces James Guest, M.D., Ph.D., Has Joined Scientific Advisory Board
Business Wire - Mon Jun 15, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that James Guest, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Guest is currently a Professor of Neurological Surgery at the Miller School of Medicine and the Miami Project to Cure Paralysis in Miami, FL.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Enrollment of Third Patient in Pilot Spinal Cord Injury Trial
Business Wire - Fri Jun 05, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a third patient has been enrolled in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC.
NVIV: 16.69 (+0.13)
InVivo Therapeutics' Neuro-Spinal Scaffold Featured on NBC's TODAY Show
Business Wire - Wed Jun 03, 11:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) has announced that the company's investigational Neuro-Spinal Scaffold was featured on NBC's TODAY show this morning. Two patients enrolled in InVivo's clinical study were featured along with Nicholas Theodore, M.D., Chief of Spinal Surgery, Barrow Neurosurgical Institute and Medical Director of the Neurological Trauma Program. Dr. Theodore, the Principal Investigator who implanted the first-ever Neuro-Spinal Scaffold into an acute spinal cord injury patient, made comments relating to the implantation procedure and provided his medical opinion on the technology.
NVIV: 16.69 (+0.13)
InVivo Therapeutics' Neuro-Spinal Scaffold Receives 2015 Becker's Healthcare Spine Device Award
Business Wire - Mon Jun 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company's investigational Neuro-Spinal Scaffold has received the 2015 Becker's Healthcare Spine Device Award. It is one of 25 devices that received this distinction from Becker's Healthcare. According to their article, "Both 'tried-and-true' devices as well as new promising innovations are featured in this year's awards." Award nominees are determined by the publication's editorial staff, in this case Becker's Spine Review, and are vetted by a panel of industry experts.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Indiana's Goodman Campbell Brain and Spine as New Site for Neuro-Spinal Scaffold Clinical Trial
Business Wire - Tue May 19, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Goodman Campbell Brain and Spine in Indianapolis, IN has been added as a clinical site in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Goodman Campbell Brain and Spine is the merger of two highly-respected institutions: Indianapolis Neurosurgical Group and Indiana University Department of Neurological Surgery, providing a complement of exceptional medical-practice expertise and world-renowned academic research. Procedures will be performed at Indiana University Health Methodist Hospital. Eric Horn, M.D., Ph.D., Assistant Professor of Neurological Surgery and Director of Spinal Neurosurgery at Indiana University Department of Neurological Surgery, has been named Principal Investigator at this site.
NVIV: 16.69 (+0.13)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon May 18, 11:46AM CDT
RGSE: 1.49 (+0.07), SGYP: 8.68 (-0.03), BOSC: 2.16 (-0.09), VTNR: 2.01 (-0.04), LTBR: 0.91 (-0.03), MNGA: 1.09 (-0.03), YUMA: 0.56 (+0.18), TCX: 31.59 (+1.96), PFNX: 21.92 (-0.75), GBR: 1.40 (-0.06), GTXI: 1.32 (-0.02), SOFO: 6.43 (+0.13), SDT: 4.62 (-0.04), UWN: 1.73 (-0.04), NVIV: 16.69 (+0.13), FSAM: 10.04 (unch), CHKR: 5.34 (-0.44), ICLD: 2.23 (+0.05), DXM: 0.49 (+0.01), OSUR: 5.17 (-0.13)
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 187.07 (-0.57), VRTX: 130.97 (-2.50), OVAS: 29.29 (+0.08), MYL: 67.21 (+0.23), AMGN: 163.70 (-0.64), GSK: 42.63 (-0.39), ALR: 51.37 (-0.40), ONTY: 3.62 (-0.04), CELG: 136.24 (+1.01), PVCT: 0.46 (unch), JNJ: 100.34 (-0.03), OREX: 4.15 (-0.18), FCSC: 5.85 (+0.19), NVIV: 16.69 (+0.13), GILD: 117.78 (-0.42), GWPH: 123.91 (-1.94), CTSO: 6.64 (+0.07), ACHN: 9.26 (-0.10), RMD: 56.76 (-0.36), SNY: 52.99 (-0.26), PBYI: 99.72 (-3.54)
Explaining InVivo's Update
Jason Napodano, CFA - Seeking Alpha - Thu May 14, 11:33AM CDT
On May 14, 2015, InVivo Therapeutics ( OTCQB:NVIV ) provided an update on the status of the two patients enrolled so far in the company's investigational pilot study with the neuro-spinal scaffolding (NSS) device. We remind investors that...
NVIV: 16.69 (+0.13)
InVivo Therapeutics Reports Update of First Two Spinal Cord Injury Patients Implanted with Neuro-Spinal Scaffold
Business Wire - Thu May 14, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced a six-month post-implant update for the first study patient and a three-month post-implant update for the second study patient in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the first patient in October 2014 at the Barrow Neurological Institute, Phoenix, AZ and in the second patient in January 2015 at the Carolinas Medical Center, Charlotte, NC.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Reports 2015 First Quarter Financial Results and Business Update
Business Wire - Thu May 07, 5:00PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2015.
NVIV: 16.69 (+0.13)
Orphan Drug Product Candidate Development Provides Revolutionary Solutions for Treatment of Severe Injuries and Innovative Therapies for Rare Diseases & Conditions
PR Newswire - Wed Jul 15, 7:15AM CDT
As modern biotechnology continues to provide breakthrough products and technologies to combat debilitating rare diseases, treat severe injuries and offer therapeutic treatments for many areas of various medical conditions, today's leading biotech & biopharmaceutical companies such as Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Receptos, Inc. (NASDAQ: RCPT) race to introduce the newest technologies and products that help improve the lives and overall health of patients worldwide.
NVIV: 16.69 (+0.13), CLDX: 25.56 (-0.83), RCPT: 228.98 (+0.26), EPRS: 6.99 (-0.66), ARIA: 8.24 (-0.17), CELG: 136.24 (+1.01)
Third patient receiving InVivo's Neuro-Spinal Scaffold shows encouraging progress, shares up 10% premarket
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 8:26AM CDT
NVIV: 16.69 (+0.13)
InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold
Business Wire - Mon Jul 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury.
NVIV: 16.69 (+0.13)
InVivo Therapeutics to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
Business Wire - Wed Jul 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at Cantor Fitzgerald's Inaugural Healthcare Conference to be held Wednesday, July 8, 2015 at Le Parker Meridien Hotel in New York City, NY. The company's presentation will be at 10:45 A.M. (EDT).
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Rutgers New Jersey Medical School as New Clinical Site for Neuro-Spinal Scaffold
Business Wire - Tue Jun 30, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Rutgers New Jersey Medical School in Newark, NJ has been added as a clinical site in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Robert Heary, M.D., Professor of Neurological Surgery and Director of the Spine Center, has been named Principal Investigator at this site. The Spine Center is part of the Northern New Jersey Spinal Cord Injury System, one of 14 federally designated Spinal Cord Injury Model Systems in the United States and the only one in the state of New Jersey.
NVIV: 16.69 (+0.13)
InVivo Therapeutics is Added to Russell Global, Russell 3000(R), Russell 2000(R), and Russell Microcap(R) Indexes
Business Wire - Mon Jun 29, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company has been added to the Russell Global, Russell 3000(R), Russell 2000(R), and Russell Microcap (R) Indexes on June 26, 2015.
NVIV: 16.69 (+0.13)
InVivo Therapeutics up 5% premarket on patent award covering Neuro-Spinal Scaffold
Seeking Alpha - at Seeking Alpha - Mon Jun 22, 8:16AM CDT
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders Meeting
Business Wire - Fri Jun 19, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the posting of the management presentation recording from the 2015 Annual Shareholders Meeting held on June 16th, 2015. The recording is available on the investor relations page of InVivo's website - http://www.invivotherapeutics.com/investor-re...l-meeting/.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Co-Founder Dr. Robert Langer to Highlight InVivo Scientific Progress in Closing Keynote Address at the International Society for Stem Cell Research 2015 Annual Meeting
Business Wire - Thu Jun 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Co-Founder Robert Langer, Sc.D., will be making the Closing Keynote Address at the Annual Meeting of the International Society for Stem Cell Research (ISSCR), to be held June 24-27, 2015 in Stockholm, Sweden. His keynote address will be held during the last plenary session titled Making Tissues and Organs.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Appointment of Ann Merrifield as Lead Director
Business Wire - Tue Jun 16, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the Company's Board of Directors has appointed independent director Ann Merrifield to the newly created position of Lead Director. The Lead Director will serve as a liaison between the Chairman and non-management directors, chair all executive sessions, and work with the Chairman on meeting agendas and time schedules for the Board of Directors.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces James Guest, M.D., Ph.D., Has Joined Scientific Advisory Board
Business Wire - Mon Jun 15, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that James Guest, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Guest is currently a Professor of Neurological Surgery at the Miller School of Medicine and the Miami Project to Cure Paralysis in Miami, FL.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Enrollment of Third Patient in Pilot Spinal Cord Injury Trial
Business Wire - Fri Jun 05, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a third patient has been enrolled in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC.
NVIV: 16.69 (+0.13)
InVivo Therapeutics' Neuro-Spinal Scaffold Featured on NBC's TODAY Show
Business Wire - Wed Jun 03, 11:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) has announced that the company's investigational Neuro-Spinal Scaffold was featured on NBC's TODAY show this morning. Two patients enrolled in InVivo's clinical study were featured along with Nicholas Theodore, M.D., Chief of Spinal Surgery, Barrow Neurosurgical Institute and Medical Director of the Neurological Trauma Program. Dr. Theodore, the Principal Investigator who implanted the first-ever Neuro-Spinal Scaffold into an acute spinal cord injury patient, made comments relating to the implantation procedure and provided his medical opinion on the technology.
NVIV: 16.69 (+0.13)
InVivo Therapeutics' Neuro-Spinal Scaffold Receives 2015 Becker's Healthcare Spine Device Award
Business Wire - Mon Jun 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company's investigational Neuro-Spinal Scaffold has received the 2015 Becker's Healthcare Spine Device Award. It is one of 25 devices that received this distinction from Becker's Healthcare. According to their article, "Both 'tried-and-true' devices as well as new promising innovations are featured in this year's awards." Award nominees are determined by the publication's editorial staff, in this case Becker's Spine Review, and are vetted by a panel of industry experts.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Announces Indiana's Goodman Campbell Brain and Spine as New Site for Neuro-Spinal Scaffold Clinical Trial
Business Wire - Tue May 19, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Goodman Campbell Brain and Spine in Indianapolis, IN has been added as a clinical site in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Goodman Campbell Brain and Spine is the merger of two highly-respected institutions: Indianapolis Neurosurgical Group and Indiana University Department of Neurological Surgery, providing a complement of exceptional medical-practice expertise and world-renowned academic research. Procedures will be performed at Indiana University Health Methodist Hospital. Eric Horn, M.D., Ph.D., Assistant Professor of Neurological Surgery and Director of Spinal Neurosurgery at Indiana University Department of Neurological Surgery, has been named Principal Investigator at this site.
NVIV: 16.69 (+0.13)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon May 18, 11:46AM CDT
RGSE: 1.49 (+0.07), SGYP: 8.68 (-0.03), BOSC: 2.16 (-0.09), VTNR: 2.01 (-0.04), LTBR: 0.91 (-0.03), MNGA: 1.09 (-0.03), YUMA: 0.56 (+0.18), TCX: 31.59 (+1.96), PFNX: 21.92 (-0.75), GBR: 1.40 (-0.06), GTXI: 1.32 (-0.02), SOFO: 6.43 (+0.13), SDT: 4.62 (-0.04), UWN: 1.73 (-0.04), NVIV: 16.69 (+0.13), FSAM: 10.04 (unch), CHKR: 5.34 (-0.44), ICLD: 2.23 (+0.05), DXM: 0.49 (+0.01), OSUR: 5.17 (-0.13)
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 187.07 (-0.57), VRTX: 130.97 (-2.50), OVAS: 29.29 (+0.08), MYL: 67.21 (+0.23), AMGN: 163.70 (-0.64), GSK: 42.63 (-0.39), ALR: 51.37 (-0.40), ONTY: 3.62 (-0.04), CELG: 136.24 (+1.01), PVCT: 0.46 (unch), JNJ: 100.34 (-0.03), OREX: 4.15 (-0.18), FCSC: 5.85 (+0.19), NVIV: 16.69 (+0.13), GILD: 117.78 (-0.42), GWPH: 123.91 (-1.94), CTSO: 6.64 (+0.07), ACHN: 9.26 (-0.10), RMD: 56.76 (-0.36), SNY: 52.99 (-0.26), PBYI: 99.72 (-3.54)
Explaining InVivo's Update
Jason Napodano, CFA - Seeking Alpha - Thu May 14, 11:33AM CDT
On May 14, 2015, InVivo Therapeutics ( OTCQB:NVIV ) provided an update on the status of the two patients enrolled so far in the company's investigational pilot study with the neuro-spinal scaffolding (NSS) device. We remind investors that...
NVIV: 16.69 (+0.13)
InVivo Therapeutics Reports Update of First Two Spinal Cord Injury Patients Implanted with Neuro-Spinal Scaffold
Business Wire - Thu May 14, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced a six-month post-implant update for the first study patient and a three-month post-implant update for the second study patient in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the first patient in October 2014 at the Barrow Neurological Institute, Phoenix, AZ and in the second patient in January 2015 at the Carolinas Medical Center, Charlotte, NC.
NVIV: 16.69 (+0.13)
InVivo Therapeutics Reports 2015 First Quarter Financial Results and Business Update
Business Wire - Thu May 07, 5:00PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2015.
NVIV: 16.69 (+0.13)
